Nura El-Haj
Research Subjects
Nura El-Haj has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Eric C. Ko
UMass Chan Medical School
1 shared publication - Fran Laurie1 shared publication
- Ghazala Naheed Usmani
University of Massachusetts Memorial Medical Center Worcester, MA United States
1 shared publication - Julia Hayden1 shared publication
- Koren Smith1 shared publication
- Maryann Bishop-Jodoin1 shared publication
Latest Publications
- Open Access
- 21 June 2024
- Published by IntechOpen
Medulloblastoma: Systemic Chemotherapy and Future Applications of Chemoradiotherapy
Medulloblastoma is the most common malignant brain tumor in children. Prognosis remains guarded in patients who at diagnosis are very young, have craniospinal metastatic disease, or after resection, have residual disease. Treatment incorporates chemotherapy and radiation therapy. Cancer survivors often have life-altering treatment effects. This chapter reviews clinical trials over the years and the efforts to improve survival and minimize sequelae along with challenges in performing clinical trials. Quality assurance of the radiation therapy provided worldwide monitors compliance. Advances in the risk stratification and targeted treatment based on the genomics and biology of medulloblastoma are highlighted in recent clinical trials. Through chemotherapy aligned with specific biomarkers, sophisticated radiation therapy strategies, and continued quality assurance, the future vision of managing medulloblastoma is presented.
- 21 June 2024
- Published by IntechOpen
Open AccessMedulloblastoma: Systemic Chemotherapy and Future Applications of Chemoradiotherapy
Medulloblastoma is the most common malignant brain tumor in children. Prognosis remains guarded in patients who at diagnosis are very young, have craniospinal metastatic disease, or after resection, have residual disease. Treatment incorporates chemotherapy and radiation therapy. Cancer survivors often have life-altering treatment effects. This chapter reviews clinical trials over the years and the efforts to improve survival and minimize sequelae along with challenges in performing clinical trials. Quality assurance of the radiation therapy provided worldwide monitors compliance. Advances in the risk stratification and targeted treatment based on the genomics and biology of medulloblastoma are highlighted in recent clinical trials. Through chemotherapy aligned with specific biomarkers, sophisticated radiation therapy strategies, and continued quality assurance, the future vision of managing medulloblastoma is presented.